{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vitamin+K+antagonist+%28VKA%29&page=2", "query": { "intervention": "Vitamin K antagonist (VKA)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vitamin+K+antagonist+%28VKA%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vitamin+K+antagonist+%28VKA%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T13:48:23.506Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02687867", "title": "Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Dabigatran (Pradaxa)", "type": "DRUG" }, { "name": "Vitamin K antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56039, "start_date": "2016-02-12", "completion_date": "2016-03-01", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02687867" }, { "nct_id": "NCT04045665", "title": "Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Bleeding" ], "interventions": [ { "name": "Antiplatelet-only strategy", "type": "DRUG" }, { "name": "Oral Anticoagulant plus background antiplatelet therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3200, "start_date": "2019-12-13", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04045665" }, { "nct_id": "NCT01674647", "title": "Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1504, "start_date": "2012-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 66, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "East Palo Alto", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674647" }, { "nct_id": "NCT01830543", "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Percutaneous Coronary Intervention" ], "interventions": [ { "name": "rivaroxaban 2.5 mg", "type": "DRUG" }, { "name": "rivaroxaban 15 mg", "type": "DRUG" }, { "name": "rivaroxaban 10 mg", "type": "DRUG" }, { "name": "aspirin (ASA)", "type": "DRUG" }, { "name": "vitamin K antagonist (VKA)", "type": "DRUG" }, { "name": "clopidogrel", "type": "DRUG" }, { "name": "prasugrel", "type": "DRUG" }, { "name": "ticagrelor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2124, "start_date": "2013-05-10", "completion_date": "2016-07-28", "has_results": true, "last_update_posted_date": "2017-09-19", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 86, "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830543" }, { "nct_id": "NCT02981472", "title": "A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombosis" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Vitamin K Antagonist (VKA)", "type": "DRUG" }, { "name": "Low Molecular Weight Heparin (LMWH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 192, "start_date": "2017-01-19", "completion_date": "2021-10-18", "has_results": true, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 14, "location_summary": "Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981472" }, { "nct_id": "NCT00067093", "title": "Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Deep Vein Thrombosis" ], "interventions": [ { "name": "SanOrg34006", "type": "DRUG" }, { "name": "LMW heparin", "type": "DRUG" }, { "name": "Unfractionated heparin", "type": "DRUG" }, { "name": "Vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1452, "start_date": "2003-05", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2011-04-06", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 24, "location_summary": "Denver, Colorado • Jacksonville, Florida • Melbourne, Florida + 21 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067093" }, { "nct_id": "NCT02740335", "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Significant Bleeding Risk" ], "interventions": [ { "name": "Octaplex", "type": "DRUG" }, { "name": "Beriplex P/N (Kcentra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2017-06-08", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2023-03-08", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 22, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740335" }, { "nct_id": "NCT06429787", "title": "Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Vitamin K-Dependent Coagulation Defect", "Significant Bleeding Risk" ], "interventions": [ { "name": "Balfaxar", "type": "DRUG" }, { "name": "Kcentra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3574, "start_date": "2025-02-14", "completion_date": "2032-06-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06429787" }, { "nct_id": "NCT02556203", "title": "Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transcatheter Aortic Valve Replacement" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Acetylsalicylic Acid (ASA)", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1653, "start_date": "2015-12-16", "completion_date": "2018-11-27", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 31, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556203" }, { "nct_id": "NCT03374540", "title": "Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nonvalvular Atrial Fibrillation" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78517, "start_date": "2017-12-01", "completion_date": "2019-08-30", "has_results": false, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-10-09T13:48:23.506Z", "location_count": 1, "location_summary": "Multiple Locations, Washington", "locations": [ { "city": "Multiple Locations", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374540" } ] }